NCT05831007View on ClinicalTrials.gov

Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

NAUnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC

LX102-C01 Injection

Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

Innostellar Biotherapeutics

UNKNOWN

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER